Unexplained weight loss (UWL), defined as a loss of 5% or more of total body weight within a six-month period, is a common but challenging diagnostic dilemma in clinical practice. This article aims to provide a comprehensive approach to the evaluation of unexplained weight loss.
UWL can be the result of various underlying conditions, ranging from malignancy, gastrointestinal disorders, endocrine abnormalities, to psychiatric disorders. In some cases, despite extensive evaluation, no cause is found, leading to a diagnosis of idiopathic UWL.
The first step in the evaluation of UWL is a detailed history and physical examination. Key elements to be elicited include the time course of weight loss, associated symptoms, dietary history, medication use, and psychosocial history. A thorough physical examination can also provide clues to the underlying etiology.
If the history and physical examination do not reveal a cause, further investigations are warranted. Basic laboratory tests, including complete blood count, comprehensive metabolic panel, thyroid function tests, and urinalysis, should be performed. Imaging studies, such as chest radiography and abdominal ultrasonography, may also be considered based on the clinical suspicion.
The management of UWL is primarily directed towards the underlying cause. In cases of idiopathic UWL, the focus should be on symptom management and regular monitoring for the emergence of new symptoms or signs that may point to an underlying disease.
UWL is a complex clinical problem that requires a systematic and comprehensive approach. A thorough history and physical examination, followed by targeted laboratory and imaging investigations, form the cornerstone of evaluation. Management is etiology-specific, with idiopathic cases requiring careful monitoring and supportive care.
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation